CpG Island Methylator Phenotype May Predict Poor Overall Survival of Patients with Stage IV Colorectal Cancer

Oncology ◽  
2018 ◽  
Vol 96 (3) ◽  
pp. 156-163
Author(s):  
Kuo-Hsing  Chen ◽  
Liang-In  Lin ◽  
Li-Hui  Tseng ◽  
Yu-Lin Lin ◽  
Jau-Yu Liau ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Cpg Island ◽  
Stage Iv ◽  
Cpg Island Methylator Phenotype ◽  
Poor Overall Survival ◽  
Stage Iv Colorectal Cancer ◽  
Methylator Phenotype

scholarly journals CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Xia Li ◽  
Fulan Hu ◽  
Yibaina Wang ◽  
Xiaoping Yao ◽  
Zuoming Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Promoter Methylation ◽  
Northeast China ◽  
Proportional Hazards ◽  
Cpg Island ◽  
Sporadic Colorectal Cancer ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype ◽  
Worse Prognosis

Purpose. To investigate the association between CpG island methylator phenotype (CIMP) and the overall survival of sporadic colorectal cancer (CRC) in Northeast China.Methods. 282 sporadic CRC patients were recruited in this study. We selectedMLH1,MGMT,p16,APC,MINT1,MINT31, andRUNX3as the CIMP panel markers. The promoter methylation was assessed by methylation sensitive high resolution melting (MS-HRM). Proportional hazards-regression models were fitted with computing hazard ratios (HR) and the corresponding 95% confidence intervals (95% CI).Results. 12.77% (36/282) of patients were CIMP-0, 74.1% (209/282) of patients were CIMP-L, and 13.12% (37/282) of patients were CIMP-H. The five-year survival of the 282 CRC patients was 58%. There was significant association betweenAPCgene promoter methylation and CRC overall survival (HR = 1.61; 95% CI: 1.05–2.46;P=0.03). CIMP-H was significantly associated with worse prognosis compared to CIMP-0 (HR = 3.06; 95% CI: 1.19–7.89;P=0.02) and CIMP-L (HR = 1.97; 95% CI: 1.11–3.48;P=0.02), respectively. While comparing with the combine of CIMP-L and CIMP-0 (CIMP-L/0), CIMP-H also presented a worse prognosis (HR = 2.31; 95% CI: 1.02–5.24;P=0.04).Conclusion. CIMP-H may be a predictor of a poor prognosis of CRC in Northeast China patients.

The prognostic role of CpG island methylator phenotype in metastatic colorectal cancer.

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 667-667
Author(s):  
Kuo-Hsing Chen ◽  
Liang-In Lin ◽  
Li-Hui Tseng ◽  
Yu-Lin Lin ◽  
Jau-Yu Liau ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Overall Survival ◽  
Cpg Island ◽  
Rank Test ◽  
Prognostic Role ◽  
Cpg Island Methylator Phenotype ◽  
Poor Prognostic Factor ◽  
Significant Difference ◽  
Methylator Phenotype

667 Background: The prognostic role of CpG Island Methylator Phenotype (CIMP) in colorectal cancer (CRC) is still controversial, especially in metastatic CRC. Methods: We retrospectively analyzed the CpG island methylator phenotype (CIMP) in stage I to IV CRC specimens, which were diagnosed during 2005-2013. CIMP status was determined using a 5- gene MethyLight-based assay ( p16, MINT1, MINT2, MINT31, and MLH1). Tumors were designated as CIMP if 3 or more of 5 genes gave percent of methylated reference value ≧ 10. The clinicopatholoical characteristics, anti-cancer therapies, and the overall survival outcome were reviewed. Overall survival (OS) was compared between patients with CIMP CRC and those with non-CIMP CRC. Results: Among 450 patients with successfully determined CIMP status, 259 (57.56%) were male, 312 (70.31%) were stages I-III, 316 (70.69%) were left-sided CRC. In the survival analyses in stages I-IV patients, there was no significant difference in OS between those with or without CIMP (long rank test, p = 0.4526). Importantly, patients with metastatic CIMP CRC had poor OS than those with metastatic non-CIMP CRC (median survival, CIMP vs. non-CIMP: 1.36 vs. 3.11 years, log rank test, p = 0.0047). In a multivariate analysis, which adjusted prognostic variables such as: KRAS and BRAF mutations, microsatellite instability status, age, sex, grade, primary site, metastatic site number, chemotherapies and targeted therapies, CIMP remained an independent poor prognostic factor for OS (HR = 6.213, 95% confidence interval: 2.443 to 15.799, p = 0.0001) in metastatic CRC. In an exploratory analysis, there were more tumors with liver metastases at diagnosis in CIMP CRC than in non-CIMP CRC (94.4% vs. 71.3%, p = 0.0416). Conclusions: Our data demonstrated CIMP might independently predict poor survival in metastatic CRC in a large East Asian cohort.

scholarly journals The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

2010 ◽  
Vol 16 (6) ◽  
pp. 1845-1855 ◽  
Author(s):  
Anna M. Dahlin ◽  
Richard Palmqvist ◽  
Maria L. Henriksson ◽  
Maria Jacobsson ◽  
Vincy Eklöf ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microsatellite Instability ◽  
Cpg Island ◽  
Cancer Prognosis ◽  
Cpg Island Methylator Phenotype ◽  
Methylator Phenotype

scholarly journals CpG Island Methylator Phenotype-Low (CIMP-Low) in Colorectal Cancer: Possible Associations with Male Sex and KRAS Mutations

2006 ◽  
Vol 8 (5) ◽  
pp. 582-588 ◽  
Author(s):  
Shuji Ogino ◽  
Takako Kawasaki ◽  
Gregory J. Kirkner ◽  
Massimo Loda ◽  
Charles S. Fuchs
Keyword(s):  
Colorectal Cancer ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
Kras Mutations ◽  
Male Sex ◽  
Methylator Phenotype

scholarly journals IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype

2009 ◽  
Vol 31 (3) ◽  
pp. 342-349 ◽  
Author(s):  
Hiromu Suzuki ◽  
Shinichi Igarashi ◽  
Masanori Nojima ◽  
Reo Maruyama ◽  
Eiichiro Yamamoto ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cpg Island ◽  
Cpg Island Methylator Phenotype ◽  
Responsive Gene ◽  
Methylator Phenotype

Determination & expression of chimeric protein in colorectal cancer: A bioinformatics Approach

2021 ◽  
Vol 2 (3) ◽  
pp. 35-67
Author(s):  
Gargi Bhattacharyya ◽  
Amit Chattopadhay
Keyword(s):  
Colorectal Cancer ◽  
Cpg Island ◽  
Therapeutic Process ◽  
Chimeric Protein ◽  
Ageing Population ◽  
Cpg Island Methylator Phenotype ◽  
High Risk Factors ◽  
Bowel Movements ◽  
Methylator Phenotype ◽  
New Treatments

Colorectal cancer (CRC) accounts for about 10% of cancer-related mortality in western countries. Increasing ageing population, undesirable modern dietary and high-risk factors like smoking, obesity and low exercise. Chromosomal instability (CIN), CpG island methylator phenotype (CIMP), and microsatellite instability are the three different mechanism that give rise to CRC. It often grow slowly, and customarily doesn’t produce symptoms until reaching a substantial size of several centimeters, which can block the passage of feces and cause cramping, pain, or bleeding which can present as visible bleeding with bowel movements or, rarely, dark “tarry” stools. Most colon tumors develop via a several different processes involving a series of histological, morphological, and genetical changes that accumulate over time to time. New treatments for primary and metastatic colorectal cancer have emerged, like in variety of therapeutic process by preparing chimeric proteins that triggers the cells and stop it from getting severe.

Sign in / Sign up

Export Citation Format

Share Document